News
04 Sep 2026
NILLOW Trial in Chronic Myeloid Leukaemia
Dr. Deepak Garg is a co-investigator and joint first author of the NILLOW phase II randomised trial conducted at AIIMS New Delhi, investigating a reduced-dose approach to second-generation tyrosine kinase inhibitor therapy in newly diagnosed chronic-phase chronic myeloid leukaemia.
Read more